Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
:LXRX
LXRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.28 - $2.45
Previous CloseN/A
Volume2.02M
Average Volume (3M)7.76M
Market Cap
$206.23M
Enterprise Value$415.05M
Total Cash (Recent Filing)$66.66M
Total Debt (Recent Filing)$108.40M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
May 01, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding361,492,300
10 Day Avg. Volume4,165,696
30 Day Avg. Volume7,762,907
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.22
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap2.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.62
Enterprise Value/Ebitda-2.24
Forecast
1Y Price Target
$3.67Price Target Upside543.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Financial PositionLexicon ended 2024 with $238M in cash/investments, which is believed to provide sufficient capital through early 2026.
R&D PipelineLexicon's R&D programs are concentrated on pilavapadin (LX9211) in DPNP, which demonstrated meaningful reductions and a well-tolerated safety profile in the Phase 2b PROGRESS study.
Strategic PartnershipsThe agreement with a major player in the diabetes and obesity space validates the potential of LX9851 as a first-in-class, non-incretin candidate for metabolic disorders.
Bears Say
Clinical Trial ChallengesLexicon may continue to face investor pressure with their recent Ph.2b PROGRESS data for pilavapadin in diabetic peripheral neuropathic pain, which was viewed as mixed with only the 10mg dose arm showing meaningful separation vs placebo.
Commercial ChallengesThe launch of Inpefa in heart failure has slowed, leading to potential cash runway concerns for Lexicon Pharmaceuticals.
Market CompetitionThe competitive landscape is evolving with new approvals, adding challenges for Lexicon Pharmaceuticals in achieving commercial success.
---
Ownership Overview
51.08% Insiders
11.75% Mutual Funds
0.25% Other Institutional Investors
32.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.28 and its highest was $2.45 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $206.23M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 32 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Mar 06, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.127 by $0.037.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.09.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 361,492,300 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.127. Following the earnings report the stock price went up 5.405%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
---
Lexicon Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.67 (543.86% Upside)
$3.67 (543.86% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.25%
12-Months-Change
Fundamentals
Return on Equity
-167.66%
Trailing 12-Months
Asset Growth
30.07%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
---
LXRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed outlook. While there were significant achievements in clinical trials, licensing agreements, and financial position improvements, these were balanced by increased net losses, operating expenses, and market challenges in the US heart failure sector.Read More>---
LXRX Stock 12 Month Forecast
Average Price Target
$3.67
▲(543.86% Upside)
Technical Analysis
Best Analysts Covering LXRX
1 Year
1 Year Success Rate
5/17 ratings generated profit
1 Year Average Return
-17.09%
reiterated a buy rating 4 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -17.09% per trade.
---